Published in Int J Exp Pathol on September 15, 2009
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther (2005) 3.27
Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation (2001) 2.21
Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol (1986) 2.04
Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int (1999) 1.66
The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology (2002) 1.57
Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol (1991) 1.19
Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res (2004) 1.17
Plasma renin level in hepatic cirrhosis. Relaton to functional renal failure. Am J Med (1970) 1.14
Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol (1998) 1.14
The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther (2001) 1.09
Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest (1992) 1.08
Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology (1993) 1.06
Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. Biochem Pharmacol (1987) 1.05
Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis. J Am Soc Nephrol (1996) 1.03
Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J (1993) 0.99
Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int (1991) 0.96
Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem Pharmacol (1995) 0.95
Cyclic 3',5'-nucleotide diesterases in dynamics of cAMP and cGMP in rat collecting duct cells. Am J Physiol (1992) 0.94
Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost (2004) 0.92
Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Br J Pharmacol (2003) 0.92
Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br J Pharmacol (1994) 0.91
Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation. Kidney Int (2001) 0.89
Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile-duct ligation. J Am Soc Nephrol (1996) 0.88
Chelerythrine, a protein kinase C inhibitor, interacts with cyclic nucleotide phosphodiesterases. Eur J Pharmacol (1997) 0.88
Characterisation of cyclic nucleotide phosphodiesterases from rat mesenteric artery. Eur J Pharmacol (1991) 0.88
Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.88
Measurements of cyclic AMP and cyclic GMP phosphodiesterase activity in isolated tubular segments. Kidney Int (1980) 0.86
Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol Biol (2005) 0.85
Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells. Eur J Pharmacol (1995) 0.85
Cyclic nucleotide phosphodiesterases in glomeruli of rat renal cortex. Kidney Int (1978) 0.83
Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis. Am J Physiol Heart Circ Physiol (2006) 0.83
Uncoupling of vasopressin signaling in collecting ducts from rats with CBL-induced liver cirrhosis. Am J Physiol Renal Physiol (2004) 0.82
Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology (2000) 0.79
Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Am J Physiol (1996) 0.79
Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites. Liver Int (2005) 0.78
Phosphodiesterases in the rat renal vasculature. J Cardiovasc Pharmacol (1997) 0.77
Atrial natriuretic peptide: renal effects in cirrhosis of the liver. Semin Nephrol (1997) 0.77
Role of vascular nitric oxide in experimental liver cirrhosis. Curr Vasc Pharmacol (2005) 0.77
Localization of low-KM cAMP phosphodiesterase in rat nephron segments. Kidney Blood Press Res (1997) 0.76
Vasoactive factors in the mechanism of renal sodium handling in cirrhotics: the effect of acute plasma expansion. Pharmacol Res Commun (1984) 0.76
Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg Med Chem (2002) 2.03
Using team-based learning to teach pharmacology to second year medical students improves student performance. Med Teach (2010) 1.98
Negative feedback exerted by cAMP-dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes: an in vivo study using adenovirus-mediated expression of CNG channels. J Biol Chem (2004) 1.33
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol (2012) 1.26
Alternating ibuprofen and acetaminophen in the treatment of febrile children: a pilot study [ISRCTN30487061]. BMC Med (2006) 1.07
Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals. Circ Res (2009) 1.03
VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost (2003) 0.96
Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res (2011) 0.95
Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/-)-naringenin. Planta Med (2005) 0.94
Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J (2003) 0.93
Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des (2010) 0.92
Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol (2009) 0.92
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors. J Med Chem (2012) 0.92
Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost (2004) 0.92
Crowd-funded micro-grants for genomics and "big data": an actionable idea connecting small (artisan) science, infrastructure science, and citizen philanthropy. OMICS (2013) 0.92
Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on angiogenesis. Cardiovasc Res (2003) 0.91
Study of the mechanisms involved in the vasorelaxation induced by (-)-epigallocatechin-3-gallate in rat aorta. Br J Pharmacol (2006) 0.91
Red wine polyphenolic compounds inhibit vascular endothelial growth factor expression in vascular smooth muscle cells by preventing the activation of the p38 mitogen-activated protein kinase pathway. Arterioscler Thromb Vasc Biol (2003) 0.90
Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS One (2010) 0.90
Teaching clinical pharmacology using team-based learning: a comparison between third- and fourth-year medical students. J Clin Pharmacol (2011) 0.88
Comparative study of the vasorelaxant activity, superoxide-scavenging ability and cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.88
Attitudes of health care professionals toward pharmacogenetic testing. Mol Diagn Ther (2011) 0.85
Assessment of phosphodiesterase isozyme contribution in cell and tissue extracts. Methods Mol Biol (2005) 0.85
Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. PLoS One (2012) 0.85
Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation. Invest New Drugs (2011) 0.84
Delphinidin inhibits endothelial cell proliferation and cell cycle progression through a transient activation of ERK-1/-2. Biochem Pharmacol (2003) 0.84
Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. Eur J Pharmacol (2010) 0.83
Effect of phosphodiesterase 5 inhibitor on alteration in vascular smooth muscle sensitivity and renal function in rats with liver cirrhosis. Am J Physiol Heart Circ Physiol (2006) 0.83
The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. Eur J Pharmacol (2009) 0.81
Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cell Signal (2010) 0.81
Endothelium-independent and endothelium-dependent vasorelaxation by a dichloromethane fraction from Anogeissus Leiocarpus (DC) Guill. Et Perr. (Combretaceae): possible involvement of cyclic nucleotide phosphodiesterase inhibition. Afr J Tradit Complement Altern Med (2012) 0.80
Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat. Eur J Pharmacol (2007) 0.80
Taurine intestinal absorption and renal excretion test in diabetic patients: a pilot study. Diabetes Care (2007) 0.80
Pharmacogenetics and personalized medicine: the future for drug prescribing. J Med Liban (2010) 0.80
NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production. Can J Physiol Pharmacol (2013) 0.80
Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor. J Med Chem (2005) 0.80
NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues. Am J Physiol Lung Cell Mol Physiol (2011) 0.79
Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition. Thromb Haemost (2014) 0.79
Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites. Liver Int (2005) 0.78
Reverse pharmacognosy: application of selnergy, a new tool for lead discovery. The example of epsilon-viniferin. Curr Drug Discov Technol (2005) 0.78
Equal antipyretic effectiveness of oral and rectal acetaminophen: a randomized controlled trial [ISRCTN11886401]. BMC Pediatr (2005) 0.78
Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. Pediatr Res (2004) 0.78
Increased levels of cyclic adenosine monophosphate contribute to the hyporesponsiveness of mast cells in alloxan diabetes. Int Immunopharmacol (2004) 0.78
Sesame oil use in ameliorating cough in children: a randomised controlled trial. Complement Ther Med (2006) 0.78
In-vivo evidence of a role for nitric oxide in regulating the activity of the norepinephrine transporter. Eur J Pharmacol (2011) 0.77
Cyclic nucleotide phosphodiesterase type 4 inhibitors: evaluation of pyrazolo[1,5-a]-1,3,5-triazine ring system as an adenine bioisostere. Eur J Med Chem (2007) 0.77
The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species. Eur J Pharmacol (2010) 0.76
New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam. Bioorg Med Chem Lett (2011) 0.75
Biflavones of Decussocarpus rospigliosii as phosphodiesterases inhibitors. Planta Med (2007) 0.75
Bioactive triterpenoids from Vochysia pacifica interact with cyclic nucleotide phosphodiesterase isozyme PDE4. Phytother Res (2005) 0.75
Foreword. Towards implementing medical ethics and bioethics education in Lebanon. J Med Liban (2011) 0.75
Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents. J Pharm Pharmacol (2004) 0.75
Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors. Eur J Med Chem (2003) 0.75